Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 171.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 831,414 shares of the biopharmaceutical company’s stock after buying an additional 524,802 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Halozyme Therapeutics were worth $39,750,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Fiduciary Alliance LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter worth $398,000. Tealwood Asset Management Inc. grew its position in Halozyme Therapeutics by 19.7% in the 4th quarter. Tealwood Asset Management Inc. now owns 52,813 shares of the biopharmaceutical company’s stock valued at $2,525,000 after acquiring an additional 8,694 shares in the last quarter. Park Avenue Securities LLC increased its stake in Halozyme Therapeutics by 6.9% during the fourth quarter. Park Avenue Securities LLC now owns 12,439 shares of the biopharmaceutical company’s stock worth $595,000 after purchasing an additional 801 shares during the period. Redhawk Wealth Advisors Inc. lifted its position in shares of Halozyme Therapeutics by 3.4% during the fourth quarter. Redhawk Wealth Advisors Inc. now owns 38,035 shares of the biopharmaceutical company’s stock worth $1,818,000 after purchasing an additional 1,267 shares in the last quarter. Finally, Outlook Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $355,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the topic of a number of research reports. Benchmark lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. lifted their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.78.

Halozyme Therapeutics Stock Down 2.8 %

Shares of NASDAQ:HALO opened at $65.86 on Friday. The firm has a 50 day simple moving average of $61.45 and a 200-day simple moving average of $55.83. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company has a market capitalization of $8.14 billion, a PE ratio of 19.20, a P/E/G ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same quarter last year, the company posted $0.79 earnings per share. The business’s quarterly revenue was up 35.2% compared to the same quarter last year. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 4,497 shares of the business’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director now directly owns 28,611 shares in the company, valued at $1,727,246.07. This represents a 13.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,697 shares of company stock worth $1,276,552 in the last quarter. 2.90% of the stock is owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.